Close



Feb 28, 2024 04:05PM
Feb 16, 2024 07:00AM
Feb 16, 2024 07:00AM
Jan 16, 2024 09:02AM
Dec 22, 2023 08:01AM
Dec 22, 2023 08:00AM
Oct 30, 2023 04:20PM Sarepta Therapeutics' (SRPT) EMBARK Study Did Not Meet Primary Endpoint but Data Shows Robust, Statistically Significant Results
Oct 30, 2023 04:01PM
Aug 2, 2023 04:05PM
Jun 22, 2023 02:02PM
Jun 22, 2023 02:02PM
May 24, 2023 10:52AM
May 24, 2023 09:06AM
May 24, 2023 08:50AM Sarepta (SRPT) tumbles 15% on 9001 decision delay; Analyst sees a buying opportunity
May 24, 2023 08:09AM
May 24, 2023 08:00AM
May 23, 2023 04:41AM
May 15, 2023 06:51AM
May 15, 2023 06:40AM
May 15, 2023 06:27AM
May 15, 2023 05:37AM Sarepta Therapeutics (SRPT) Reports Positive FDA AdCom Vote for SRP-9001
May 12, 2023 07:02PM
May 10, 2023 10:36AM
May 2, 2023 04:05PM
Apr 17, 2023 09:00PM
Apr 14, 2023 05:54AM
Apr 13, 2023 10:39AM
Apr 10, 2023 09:37AM Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
Apr 9, 2023 11:47AM
Apr 4, 2023 08:29AM
Apr 4, 2023 06:21AM
Mar 17, 2023 06:52AM
Mar 17, 2023 03:08AM
Mar 16, 2023 05:44PM
Mar 16, 2023 04:05PM Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
Feb 28, 2023 04:05PM
Mar 2, 2021 09:28AM
Mar 1, 2021 05:35PM
Feb 25, 2021 02:10PM
Feb 25, 2021 02:10PM
Nov 5, 2020 04:05PM
Aug 25, 2020 08:47AM Sarepta Therapeutics (SRPT) Said FDA Accepted Casimersen (SRP-4045) NDA for Duchenne Muscular Dystrophy, Granted Priority Review Status
Aug 25, 2020 08:45AM
Jan 13, 2020 08:36AM
Jan 13, 2020 08:30AM
Dec 12, 2019 06:19PM
Sep 17, 2019 06:48AM
Aug 19, 2019 05:57PM
Aug 19, 2019 05:48PM Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
May 8, 2019 04:05PM

13,111 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All